CoChat

PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases

Open access
Ziv, Etay, Bergen, Michael, Yarmohammadi, Hooman, Boas, F. Ed, Petre, E. Nadia, Sofocleous, Constantinos T., Yaeger, Rona, Solit, David B., Solomon, Stephen B., Erinjeri, Joseph P. · 2017 · Oncotarget
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Etay Ziv 1 , Michael Bergen 2 , Hooman Yarmohammadi 1 , F. Ed Boas 1 , E. Nadia Petre 1 , Constantinos T. Sofocleous 1 , Rona Yaeger 3 , David B. Solit 4, 5, 6 , Stephen B. Solomon 1 , Joseph P. Erinjeri 1 1 Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA 2 Department of Radiology, Mount Sinai Hospital, New York, USA 3 Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA 4 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA 5 Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA 6 Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA Correspondence to: Etay Ziv, email: zive@mskcc.org Keywords: biomarkers, colorectal, PI3K, radioembolization, MAPK Received: August 25, 2016 Accepted: January 16, 2017 Published: February 11, 2017 ABSTRACT Purpose : To establish the relationship between common mutations in the MAPK and PI3K signaling pathways and local progression after radioembolization. Materials and Methods : Retrospective review of a HIPAA-compliant institutional review-board approved database identified 40 patients with chemo-refractory colorectal liver metastases treated with radioembolization who underwent tumor genotyping for hotspot mutations in 6 key genes in the MAPK/PI3K pathways (KRAS, NRAS, BRAF, MEK1, PIK3CA, and AKT1). Mutation status as well as clinical, tumor, and treatment variables were recorded. These factors were evaluated in relation to time to local progression (TTLP), which was calculated from time of radioembolization to first radiographic evidence of local progression. Predictors of outcome were identified using a proportional hazards model for both univariate and multivariate analysis with death as a competing risk. Results : Sixteen patients (40%) had no mutations in either pathway, eighteen patients (45%) had mutations in the MAPK pathway, ten patients (25%) had mutations in the PI3K pathway and four patients (10%) had mutations in both pathways. The cumulative incidence of progression at 6 and 12 months was 33% and 55% for the PI3K mutated group compared with 76% and 92% in the PI3K wild type group. Mutation in the PI3K pathway was a significant predictor of longer TTLP in both univariate (p=0.031, sHR 0.31, 95% CI: 0.11-0.90) and multivariate (p=0.015, sHR=0.27, 95% CI: 0.096-0.77) analysis. MAPK pathway alterations were not associated with TTLP. Conclusions : PI3K pathway mutation predicts longer time to local progression after radioembolization of colorectal liver metastases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15278

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 35

Metadata

Authors
Ziv, E., Bergen, M., Yarmohammadi, H., Boas, F. E., Petre, E. N., Sofocleous, C. T., Yaeger, R., Solit, D. B., Solomon, S. B., & Erinjeri, J. P.
Venue
Oncotarget
Published
2017-02-11
Volume
8
Issue
14
Pages
23529-23538
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2588199348
Cited by
35
References
5
FWCI
2.05
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.